<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03753438</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-NASH-04</org_study_id>
    <nct_id>NCT03753438</nct_id>
  </id_info>
  <brief_title>Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics</brief_title>
  <official_title>Intragastric Balloon in Compensated NASH(Non Alcoholic Steato Hepatitis) Cirrhotics-An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted in department of Hepatology at ILBS, the patients will be&#xD;
      recruited from the OPD or IPD . The obese cirrhotic patients with NASH will be observed for&#xD;
      standard of care and also patients who undergo IGB placement as part of weight reduction&#xD;
      policy in these group of patients and will undergo an UGI endoscopy followed by placement of&#xD;
      intragastric balloon. Then the patients will be admitted for 2-3 days and followed up till 6&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2016</start_date>
  <completion_date type="Actual">May 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in weight from baseline</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in weight reduction from baseline</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in development of liver related complications</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in development of liver related complications</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of insulin resistance in both groups.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of insulin resistance in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased usage of medications for diabetes mellitus in both groups.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased usage of medications for diabetes mellitus in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased usage of medications for HOMA-IR (Homeostatic Model Assessment-Insulin Resistance) in both groups.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased usage of medications for HOMA-IR (Homeostatic Model Assessment-Insulin Resistance) in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of insulin resistance and decreased usage of medications for TNF-α (Tumor Necrosis Factor-Alpha).</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of insulin resistance and decreased usage of medications for TNF-α (Tumor Necrosis Factor-Alpha).</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver parameters such as serum albumin in both groups.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver parameters such as serum albumin in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement liver parameters such as INR in both groups</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver parameters such as INR in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver parameters such as bilirubin in both groups</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver parameters such as bilirubin in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance of esophageal varices in both groups.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance of esophageal varices in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in LSM (liver stiffness on fibroscan) in both groups</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in LSM (liver stiffness on fibroscan) in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in CAP (Controlled Attenuation Index) in both groups.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in CAP (Controlled Attenuation Index) in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in HVPG (Hepatic venous Pressure Gradient) in both groups.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in HVPG (Hepatic venous Pressure Gradient) in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver histology post completion of study in both groups.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hormonal levels such as Adiponectin level in both groups..</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hormonal levels such as Adiponectin level in both groups.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hormonal levels such as leptin level in both groups.</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hormonal levels such as Ghrelin level in both groups..</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hormonal levels such as Ghrelin level in both groups..</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hormonal levels such as Endothelin level in both groups..</measure>
    <time_frame>3 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hormonal levels such as Endothelin level in both groups..</measure>
    <time_frame>6 Month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Intragastric Balloon</arm_group_label>
    <description>Intragastric Balloon will be placed for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intragstric Ballooning</intervention_name>
    <description>Intragstric Ballooning will be put.</description>
    <arm_group_label>Intragastric Balloon</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        NASH (Non Alcoholic SteatoHepatitis) cirrhosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients between 18 and 65 years&#xD;
&#xD;
          -  NASH (Non Alcoholic SteatoHepatitis) cirrhosis&#xD;
&#xD;
          -  BMI &gt; 30 and failure to control weight despite full dietary and life style&#xD;
             modifications.&#xD;
&#xD;
          -  Compensated : CTP 6 &amp; 7 without any evidence of decompensation in form of Hepatic&#xD;
             encephalopathy, ascites, GI bleed or prolonged jaundice.&#xD;
&#xD;
          -  Small varices: Grade I varices&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcoholic liver disease&#xD;
&#xD;
          -  Advanced liver disease with ascites, hepatic encephalopathy&#xD;
&#xD;
          -  Other liver diseases such as chronic hepatitis B, chronic hepatitis C, Wilsons'&#xD;
             disease, Hemochromatosis, glycogen storage diseases etc.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unwilling patients&#xD;
&#xD;
          -  Large varices&#xD;
&#xD;
          -  Past h/o GI bleed&#xD;
&#xD;
          -  Hiatus hernia&#xD;
&#xD;
          -  Gastric ulcer&#xD;
&#xD;
          -  Severe esophagitis (Grade B and above)&#xD;
&#xD;
          -  Severe PHG or gastric erythema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiv Kumar Sarin, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver &amp; Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>November 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

